Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19111


Purpose:

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer.


Study summary:

OBJECTIVES: - Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in patients with resectable non-small cell lung cancer. - Determine the treatment-related toxicity in patients treated with this therapy. - Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients. OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection. PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.


Criteria:

DISEASE CHARACTERISTICS: - Diagnosis of malignant non-small cell lung cancer (NSCLC) - Intraoperative needle biopsy confirmation allowed - Resectable disease (stage I or II) - All tissue to be treated by radiofrequency tumor ablation must be completely contained within boundaries of planned lung resection - Medically fit to undergo lung resection PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified Other: - Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior or concurrent biologic therapy Chemotherapy: - No prior or concurrent chemotherapy Endocrine therapy: - No prior or concurrent endocrine therapy Radiotherapy: - No prior or concurrent radiotherapy Surgery: - See Disease Characteristics Other: - No other prior therapy for NSCLC


NCT ID:

NCT00039507


Primary Contact:

Study Chair
Walter J. Scott, MD, FACS
Fox Chase Cancer Center


Backup Contact:

N/A


Location Contact:

Philadelphia, Pennsylvania 19111
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.